ArticleFrontiers in oncology2019

Predictors of Long-Term Disease Control and Survival for HER2-Positive Advanced Breast Cancer Patients Treated With Pertuzumab, Trastuzumab, and Docetaxel.

Ashley M Hopkins et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.